Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity

2018/09/08 by Babikir Kheiri, Ahmed Abdalla, Mohammed Osman +7 · 25 citations
Medicine · #Chemotherapy-induced cardiotoxicity and mitigation #Cancer-related cognitive impairment studies #Chemotherapy-induced organ toxicity mitigation

paper · doi:10.1016/j.amjcard.2018.08.039

Cited by

• Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence. [europepmc]
• Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. [europepmc]
• Approaches to management of cardiovascular morbidity in adult cancer patients - cross-sectional survey among cardio-oncology experts. [europepmc]
• A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. [europepmc]
• Repurposing approved drugs for cancer therapy. [europepmc]
• Anthracycline-induced cardiotoxicity: A case report and review of literature. [europepmc]
• Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials. [europepmc]
• CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. [europepmc]
• Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. [europepmc]
• Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. [europepmc]
• Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. [europepmc]
• Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity. [europepmc]
• Effects of Carvedilol on Blood Pressure, Blood Sugar, and Blood Lipids in Elderly Patients with Refractory Hypertension. [europepmc]
• Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. [europepmc]
• Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. [europepmc]
• Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis. [europepmc]
• Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors. [europepmc]
• Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis. [europepmc]
• Carvedilol Phenocopies PGC-1α Overexpression to Alleviate Oxidative Stress, Mitochondrial Dysfunction and Prevent Doxorubicin-Induced Toxicity in Human iPSC-Derived Cardiomyocytes. [europepmc]
• Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals. [europepmc]
• Cardiotoxicity of Agents Used in Patients With Breast Cancer. [europepmc]
• Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines. [europepmc]
• The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response. [europepmc]
• Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. [europepmc]
• Cardioprotective role of antihypertensive treatment in chemotherapy-induced cardiotoxicity: umbrella review of meta-analyses of randomised controlled trials. [europepmc]